In this episode of Denatured presented by Arvinas, Jennifer Smith-Parker speaks to Arvinas President and CEO Randy Teel about the strategic discipline and leadership required to successfully refocus a company on an early-stage pipeline after a lead asset is outlicensed, discontinued or otherwise falls away — an inflection point many biotech and pharma companies face, but few navigate effectively. This episode is presented in partnership with Arvinas. Host Jennifer Smith-Parker, Director of Insights, BioSpace Guest Randy Teel, President and CEO, Arvinas

Life after the lead asset: Advancing an early-stage pipeline

BioSpace

Hi, my name is Jennifer Smith-Parker, Director of Insights at BioSpace and you're listening to Denatured. In this episode, you'll hear from Randy Thiel, President and CEO of Arvinas. We explore what it takes to rebuild and refocus a biotech pipeline after a major inflection point. From out-licensing and strategic pivots to expanding into new therapeutic areas through the lens of Arvinas' approach to platform-driven growth and portfolio design.

Hi, Randy. Thank you so much for joining this episode of Denatured. It's a pleasure to have you. If you can go ahead and introduce yourself, that would be great. Jennifer, thank you so much for having me. Really looking forward to the conversation today.

Yes, I'm Randy Thiel. I'm the CEO of Arvinas, a biotech company out of New Haven, Connecticut. And we're well-known for being the first company in the protein degrader space. So we were founded back in 2013, really to bring the idea of protein degraders or pro-tech degraders. And I can talk a little bit about that technology to bring those and try to create drugs out of those. And so the company has been around for over 10 years at this point.

We very recently crossed an important milestone of getting the first drug using our technology approved by the FDA. So a really massive milestone for us. I've been at the company as the CEO for only for about four or five months, but had a much longer history of the company of about eight years coming up in strategy, business development and a few other roles along the way. I have a history in the industry, both across biotechs.

Life after the lead asset: Advancing an early-stage pipeline

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Life after the lead asset: Advancing an early-stage pipeline

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.